comparemela.com
Home
Live Updates
Forma Therapeutics Holdings, Inc.: Forma Therapeutics Announces Presentations at Upcoming Hematology Conferences : comparemela.com
Forma Therapeutics Holdings, Inc.: Forma Therapeutics Announces Presentations at Upcoming Hematology Conferences
Updated results from the completed Phase 1 study of etavopivat in patients with sickle cell disease (SCD) Study design for the Phase 2 Gladiolus Study of etavopivat in patients with transfusion-dependent
Related Keywords
United States ,
Adam Bero ,
Santosh Saraf ,
Ashutosh Lal ,
Johanna Bennett ,
Porter Novelli ,
Patrick Kelly ,
Sickle Cell Disease Research ,
Linkedin ,
Global Congress On Sickle Cell Disease ,
European Hematology Association ,
Nasdaq ,
Exchange Commission ,
Forma Therapeutics Holdings Inc ,
Red Blood Cell Health ,
Foundation For Sickle Cell Disease Research ,
Therapeutics Holdings ,
Educational Symposium ,
Sickle Cell Disease Scientific Meeting ,
Global Congress ,
Sickle Cell Disease ,
Etavopivat Treatment ,
Sickle Cell Disease Was Well Tolerated ,
Improved Red Blood Cell ,
Open Label Study Evaluating ,
Erythrocyte Pyruvate Kinase Activator Etavopivat ,
Etavopivat Was Well Tolerated ,
Improved Red Blood Cell Health ,
Gladiolus Study ,
Open Label Trial Evaluating ,
Marilyn Telen ,
Private Securities Litigation Reform Act ,
United States Securities ,
Investor Relations ,
Reforma ,
Herapeutics ,
Oldings ,
Nnounces ,
Presentations ,
Pcoming ,
Hematology ,
Conferences ,
comparemela.com © 2020. All Rights Reserved.